Reported November 16, Roche Receives FDA Approval For Wiserdley In Combination With Everolimus For Breast Cancer Treatment
Benzinga Newsdesk 3 hours ago
FDANews
Wilserdly is the first and only next-generation all-oral SERD combination to significantly outperform standard endocrine combination in a post-CDK4/6 inhibitor setting in a head-to-head phase III trial (evERA)1
In ESR1-mutated patients Wilserdly plus everolimus significantly delayed disease progression or death by 62% compared to standard endocrine therapy plus everolimus1
ESR1 mutations are considered the primary cause of hormone therapy resistance affecting up to 40% of patients, as detected by an FDA approved test2,3
The FDA is also reviewing Wilserdly in the adjuvant setting with a decision expected by 30 November. If approved, Wilserdly will be the first SERD approved for both adjuvant and advanced ER-positive breast cancer
The FDA approval is supported by positive primary endpoint data from the phase III evERA Breast Cancer study published in The New England Journal of Medicine. In adult patients with ESR1-mutated, ER-positive, HER2-negative locally advanced or metastatic breast cancer progressing after prior cyclin-dependent kinase (CDK)4/6 inhibitor therapy, the all-oral combination of Wilserdly plus everolimus significantly prolonged progression-free survival, achieving a 62% reduction in the risk of disease progression or death compared to standard endocrine therapy plus everolimus (stratified hazard ratio=0.38; 95% confidence interval: 0.27–0.54; p<0.0001).
